Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice

被引：1267

作者：

Cherny, RA

Atwood, CS

Xilinas, ME

Gray, DN

Jones, WD

McLean, CA

Barnham, KJ

Volitakis, I

Fraser, FW

Kim, YS

Huang, XD

Goldstein, LE

Moir, RD

Lim, JT

Beyreuther, K

Zheng, H

Tanzi, RE

Masters, CL

Bush, AI ^{[1
]}

机构：

[1] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia

[2] Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia

[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Oxidat Biol Genet, Charlestown, MA 02129 USA

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Aging Unit, Charlestown, MA 02129 USA

[5] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Charlestown, MA 02129 USA

[6] Univ Gothenburg, Sahlgrenska Univ Sjukhuset, Psychiat Sect, Inst Clin Neurosci, Molndal, Sweden

[7] Biomol Res Inst, Parkville, Vic 3052, Australia

[8] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol & Genet, Charlestown, MA 02129 USA

[9] Heidelberg Univ, ZMBH, D-69120 Heidelberg, Germany

[10] Baylor Coll Med, Huffington Ctr Aging, Dept Mol & Human Genet, Houston, TX 77030 USA

来源：

NEURON | 2001年 / 30卷 / 03期

关键词：

D O I：

10.1016/S0896-6273(01)00317-8

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Inhibition of neocortical beta -amyloid (A beta) accumulation may be essential in an effective therapeutic intervention for Alzheimer's disease (AD). Cu and Zn are enriched in A beta deposits in AD, which are solubilized by Cu/Zn-selective chelators in vitro. Here we report a 49% decrease in brain A beta deposition (-375 mug/g wet weight, p = 0.0001) in a blinded study of APP2576 transgenic mice treated orally for 9 weeks with clioquinol, an antibiotic and bioavailable Cu/Zn chelator. This was accompanied by a modest increase in soluble A beta (1.45% of total cerebral A beta); APP, synaptophysin, and GFAP levels were unaffected. General health and body weight parameters were significantly more stable in the treated animals. These results support targeting the interactions of Cu and Zn with A beta as a novel therapy for the prevention and treatment of AD.

引用

页码：665 / 676

页数：12

共 51 条

[21]

KOTAKI H, 1983, J PHARMACOBIO-DYNAM, V6, P881

[22]

Kuo YM, 1996, J BIOL CHEM, V271, P4077

[23] Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains [J].

Kuo, YM ;

Kokjohn, TA ;

Beach, TG ;

Sue, LI ;

Brune, D ;

Lopez, JC ;

Kalback, WM ;

Abramowski, D ;

Sturchler-Pierrat, C ;

Staufenbiel, M ;

Roher, AE .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) :12991-12998

[24] Histochemically Reactive Zinc in Plaques of the Swedish Mutant β-Amyloid Precursor Protein Transgenic Mice [J].

Lee, JY ;

Mook-Jung, I ;

Koh, JY .

JOURNAL OF NEUROSCIENCE, 1999, 19 (11) :RC10

[25] Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease [J].

Lim, GP ;

Yang, F ;

Chu, T ;

Chen, P ;

Beech, W ;

Teter, B ;

Tran, T ;

Ubeda, O ;

Ashe, KH ;

Frautschy, SA ;

Cole, GM .

JOURNAL OF NEUROSCIENCE, 2000, 20 (15) :5709-5714

[26] Copper, iron and zinc in Alzheimer's disease senile plaques [J].

Lovell, MA ;

Robertson, JD ;

Teesdale, WJ ;

Campbell, JL ;

Markesbery, WR .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 158 (01) :47-52

[27] Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease [J].

Lue, LF ;

Kuo, YM ;

Roher, AE ;

Brachova, L ;

Shen, Y ;

Sue, L ;

Beach, T ;

Kurth, JH ;

Rydel, RE ;

Rogers, J .

AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (03) :853-862

[28] INTRAMUSCULAR DESFERRIOXAMINE IN PATIENTS WITH ALZHEIMERS-DISEASE [J].

MCLACHLAN, DRC ;

DALTON, AJ ;

KRUCK, TPA ;

BELL, MY ;

SMITH, WL ;

KALOW, W ;

ANDREWS, DF .

LANCET, 1991, 337 (8753) :1304-1308

[29]

McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO

[30]

2-M

← 1 2 3 4 5 6 →